Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.64 |
| ▸ | HEXA | P06865 | 2/20 | 0.46 |
| ▸ | HEXB | P07686 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049555 | 0.79 | DHFR (0.64) | DHFRHEXAHEXBALDH1A1HPGD | |
| SCHEMBL6049517 | 0.78 | DHFR (1.00) | DHFRHEXAHEXBALDH1A1CYP1A2 | |
| SCHEMBL3500167 | 0.74 | DHFR (0.61) | DHFRHEXAHEXBALDH1A1CYP1A2 | |
| SCHEMBL6049565 | 0.73 | DHFR (0.60) | DHFRNUDT1 | |
| SCHEMBL4526810 | 0.71 | HEXA (0.47) | DHFRHEXAHEXBALDH1A1CYP1A2 | |
| SCHEMBL6049638 | 0.71 | DHFR (0.47) | DHFRHEXAHEXBALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL4537159 | 0.70 | HEXA (0.46) | DHFRHEXAHEXBALDH1A1CYP1A2 | |
| SCHEMBL9566516 | 0.70 | SMN1; SMN2 (0.59) | ALDH1A1SMN1; SMN2HSP90AA1 | |
| Hydrochloric Acid SCHEMBL4532657 | 0.69 | HEXA (0.48) | DHFRHEXAHEXBCYP1A2 | |
| SCHEMBL24625660 | 0.69 | MYC (0.48) | ALDH1A1CYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | HTR2B, HTR1B, HTR3B | DHFR 1058/4885HEXA 748/4885HEXB 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.